Cargando…
Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012081/ https://www.ncbi.nlm.nih.gov/pubmed/31343949 http://dx.doi.org/10.1080/21645515.2019.1632683 |
_version_ | 1783496187675934720 |
---|---|
author | Vietri, Jeffrey Harnett, James Emir, Birol Chilson, Erica |
author_facet | Vietri, Jeffrey Harnett, James Emir, Birol Chilson, Erica |
author_sort | Vietri, Jeffrey |
collection | PubMed |
description | The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Data on vaccine-specific uptake among these individuals were previously unavailable. This retrospective observational study analyzed PCV13 uptake in immunocompromised patients aged 19–64 years. Data were acquired from insurance claims (N = 267,022) and electronic health records (EHR; N = 572,055) from October 2011–October 2016. Descriptive statistics were provided. Demographics were similar across the two database cohorts: mean age 49.7–51.0 years, 57–62% female, and >70% white. Iatrogenic immunosuppression was the most common high-risk category (33.3–44.2%). PCV13 uptake was 7.3% (95% CI: 7.25–7.45) in insurance claims and 9.9% (95% CI: 9.80–9.96) in EHR. Patients with HIV had the highest rate of PCV13 uptake; patients with multiple risk factors were above the mean in both cohorts. A Kaplan-Meier analysis was conducted to include patients lost to follow-up, with 441,657 and 722,071 patients for insurance claims and EHR, respectively. PCV13 uptake was only slightly higher: 9.3% (95% CI: 9.14–9.47) and 13.1% (95% CI: 12.93–13.19) for insurance claims and EHR, respectively. Four years after the ACIP 2012 recommendation, PCV13 uptake in high-risk adults aged19–64 years was low at <15% in all overall analyses. Clinicians caring for these patients should ensure adherence to the ACIP recommendation to minimize the risk of pneumococcal disease. |
format | Online Article Text |
id | pubmed-7012081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-70120812020-02-24 Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions Vietri, Jeffrey Harnett, James Emir, Birol Chilson, Erica Hum Vaccin Immunother Research Paper The CDC Advisory Committee on Immunization Practices (ACIP) recommended immunization with the recently licensed 13-valent pneumococcal conjugate vaccine (PCV13) for high-risk (immunocompromised) adults aged ≥19 years in 2012. This was in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Data on vaccine-specific uptake among these individuals were previously unavailable. This retrospective observational study analyzed PCV13 uptake in immunocompromised patients aged 19–64 years. Data were acquired from insurance claims (N = 267,022) and electronic health records (EHR; N = 572,055) from October 2011–October 2016. Descriptive statistics were provided. Demographics were similar across the two database cohorts: mean age 49.7–51.0 years, 57–62% female, and >70% white. Iatrogenic immunosuppression was the most common high-risk category (33.3–44.2%). PCV13 uptake was 7.3% (95% CI: 7.25–7.45) in insurance claims and 9.9% (95% CI: 9.80–9.96) in EHR. Patients with HIV had the highest rate of PCV13 uptake; patients with multiple risk factors were above the mean in both cohorts. A Kaplan-Meier analysis was conducted to include patients lost to follow-up, with 441,657 and 722,071 patients for insurance claims and EHR, respectively. PCV13 uptake was only slightly higher: 9.3% (95% CI: 9.14–9.47) and 13.1% (95% CI: 12.93–13.19) for insurance claims and EHR, respectively. Four years after the ACIP 2012 recommendation, PCV13 uptake in high-risk adults aged19–64 years was low at <15% in all overall analyses. Clinicians caring for these patients should ensure adherence to the ACIP recommendation to minimize the risk of pneumococcal disease. Taylor & Francis 2019-07-25 /pmc/articles/PMC7012081/ /pubmed/31343949 http://dx.doi.org/10.1080/21645515.2019.1632683 Text en © 2019 Pfizer Inc. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Research Paper Vietri, Jeffrey Harnett, James Emir, Birol Chilson, Erica Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title | Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title_full | Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title_fullStr | Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title_full_unstemmed | Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title_short | Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions |
title_sort | uptake of 13-valent pneumococcal conjugate vaccine among us adults aged 19 to 64 years with immunocompromising conditions |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012081/ https://www.ncbi.nlm.nih.gov/pubmed/31343949 http://dx.doi.org/10.1080/21645515.2019.1632683 |
work_keys_str_mv | AT vietrijeffrey uptakeof13valentpneumococcalconjugatevaccineamongusadultsaged19to64yearswithimmunocompromisingconditions AT harnettjames uptakeof13valentpneumococcalconjugatevaccineamongusadultsaged19to64yearswithimmunocompromisingconditions AT emirbirol uptakeof13valentpneumococcalconjugatevaccineamongusadultsaged19to64yearswithimmunocompromisingconditions AT chilsonerica uptakeof13valentpneumococcalconjugatevaccineamongusadultsaged19to64yearswithimmunocompromisingconditions |